Literature DB >> 9347655

Seroepidemiology of HTLV-I infection in northeast Thailand: a four year surveillance.

Y Urwijitaroon1, S Barusrux, C Puapairoj, A Romphruk, P Khampeera.   

Abstract

The human T-lymphotropic virus type I (HTLV-I) can be transmitted through blood transfusion, sexual contact, perinataly and by breast feeding. We carried out a four years seroepidemiology surveillance study of HTLV-I infection among northeast Thai population by screening for antibodies to HTLV-I (anti-HTLV-I) in 1992, 1993, 1995 and 1997. A total of 8,323 blood samples were collected from 6,228 blood donors, 832 pregnancies, 219 multitransfused patients, 53 HIV positive intravenous drug users and 1,000 northeast-Thai workers at different periods of time. The serum samples were tested for anti-HTLV-I by particle agglutination (PA) technique and confirmed by Western blot. One sample from a multitransfused patient collected in 1992 and one sample from a blood donor collected in 1995 demonstrated positive anti-HTLV-I screening by PA but negative by Western blot. This finding indicates that at present HTLV-I is not a public health problem in the northeast of Thailand but surveillance should be continually conducted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347655

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  2 in total

1.  Human T-cell lymphotropic virus type I and II seroprevalence among volunteer blood donors in Thailand.

Authors:  Sineenart Oota; Kriangsak Chaiwong; Soisaang Pikulsod; Rachanee Khuenkaew; Siriluk Pheakkhuntod; Pornthip Rattajak; Patcharakorn Kramkratok; Carlum Shiu; Sonu Bhatnagar; Tasanee Sakuldamrongpanich
Journal:  Pathog Glob Health       Date:  2018-11-14       Impact factor: 2.894

Review 2.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.